Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Toneatto

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|January 21, 2012
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled studyMaría Elena Santolaya, Miguel L O'Ryan, María Teresa Valenzuela, et al.
Vaccine|July 23, 2019
Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trialMarco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 25, 2013
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster doseMatthew D Snape, Praveen Saroey, Tessa M John, et al.
The Pediatric Infectious Disease Journal|August 21, 2013
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trialMatthew D Snape, John Philip, Tessa M John, et al.
Vaccine|May 24, 2017
Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trialFederico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2024
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical StudyTerry Nolan, Chiranjiwi Bhusal, Alejandro Hoberman, et al.
Human Vaccines & Immunotherapeutics|September 28, 2021
Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescentsTimo Vesikari, Jerzy Brzostek, Anitta Ahonen, et al.
The Pediatric Infectious Disease Journal|September 17, 2010
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trialMatthew D Snape, Tom Dawson, Philipp Oster, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2010
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancyJamie Findlow, Ray Borrow, Matthew D Snape, et al.
Human Vaccines & Immunotherapeutics|November 27, 2019
Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269Maria Stella, Maria Giuliani, Alessia Biolchi, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|January 21, 2012
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled studyMaría Elena Santolaya, Miguel L O'Ryan, María Teresa Valenzuela, et al.
Vaccine|July 23, 2019
Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trialMarco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 25, 2013
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster doseMatthew D Snape, Praveen Saroey, Tessa M John, et al.
The Pediatric Infectious Disease Journal|August 21, 2013
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trialMatthew D Snape, John Philip, Tessa M John, et al.
Vaccine|May 24, 2017
Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trialFederico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2024
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical StudyTerry Nolan, Chiranjiwi Bhusal, Alejandro Hoberman, et al.
Human Vaccines & Immunotherapeutics|September 28, 2021
Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescentsTimo Vesikari, Jerzy Brzostek, Anitta Ahonen, et al.
The Pediatric Infectious Disease Journal|September 17, 2010
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trialMatthew D Snape, Tom Dawson, Philipp Oster, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2010
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancyJamie Findlow, Ray Borrow, Matthew D Snape, et al.
Human Vaccines & Immunotherapeutics|November 27, 2019
Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269Maria Stella, Maria Giuliani, Alessia Biolchi, et al.
Pageof 5